{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:54:41Z","timestamp":1792572881908,"version":"4.5.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Psychedelic-assisted therapy with psilocybin has shown promise in Phase 2 trials for alcohol use disorder (AUD). Set and setting, particularly factors facilitating a connection with nature, may positively influence the psychedelic experience and therapeutic outcomes. But to date, randomized controlled trials of interventions to enhance set and setting for psychedelic-assisted therapy are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a pilot randomized, controlled trial of Visual Healing, a nature-themed video intervention to optimize set and setting, versus Standard set and setting procedures with two open-label psilocybin 25\u2009mg dosing sessions among 20 participants with AUD. For the first session, participants randomized to Visual Healing viewed nature-themed videos during the preparation session and the \u201cascent\u201d and \u201cdescent\u201d phases of the psilocybin dosing session while participants randomized to the Standard condition completed a meditation during the preparatory session and wore eyeshades and listened to a music playlist throughout the dosing session. For the second session 4\u2009weeks later, participants chose either Visual Healing or Standard procedures. Primary outcomes were feasibility, safety, and tolerability of Visual Healing. Secondary and exploratory outcomes were changes in alcohol use, psychedelic effects, anxiety and stress.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nineteen of 20 (95%) randomized participants (mean age 49\u2009\u00b1\u200911\u2009years, 60% female) completed the 14-week study. During the first psilocybin session, participants viewed an average of 37.9\u2009min of the 42-min video and there were no video-related adverse events. Peak increase in post-psilocybin blood pressure was significantly less for participants randomly assigned to Visual Healing compared to Standard procedures. Alcohol use decreased significantly in both Visual Healing and Standard groups and psychedelic effects, stress, and anxiety were similar between groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>In this open-label pilot study, viewing Visual Healing videos during preparation and psilocybin dosing sessions was feasible, safe, and well-tolerated among participants with AUD. Preliminary findings suggest that Visual Healing has potential to reduce the cardiovascular risks of psychedelic therapy, without interfering with the psychedelic experience or alcohol-related treatment outcomes. Studies to replicate our findings as well as studies of different set and setting interventions with other psychedelic medications and indications are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2023.1215972","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T04:01:42Z","timestamp":1695096102000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder"],"prefix":"10.3389","volume":"14","author":[{"given":"Keith G.","family":"Heinzerling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Sergi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micah","family":"Linton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhianna","family":"Rich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inez","family":"Bentancourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Bramen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabha","family":"Siddarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louie","family":"Schwartzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3389\/fphar.2018.00733","article-title":"Psychedelic-assisted psychotherapy: a paradigm shift in psychiatric research and development","volume":"9","author":"Schenberg","year":"2018","journal-title":"Front Pharmacol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1177\/070674370505000703","article-title":"Flashback: psychiatric experimentation with LSD in historical perspective","volume":"50","author":"Dyck","year":"2005","journal-title":"Can J Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1111\/ADD.15560","article-title":"What can we learn from the history of research on psychedelic drugs in the addictions?","volume":"116","author":"Hall","year":"2021","journal-title":"Addiction"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1177\/0269881112439253","article-title":"Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials","volume":"26","author":"Krebs","year":"2012","journal-title":"J Psychopharmacol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/JAMAPSYCHIATRY.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiat"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"205032451668332","DOI":"10.1177\/2050324516683325","article-title":"Constructing drug effects: a history of set and setting","volume":"3","author":"Hartogsohn","year":"2017","journal-title":"Drug Sci Policy Law"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/J.JAD.2023.01.073","article-title":"Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics","volume":"326","author":"Simonsson","year":"2023","journal-title":"J Affect Disord"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3389\/fphar.2018.00897","article-title":"Predicting responses to psychedelics: a prospective study","volume":"9","author":"Haijen","year":"2018","journal-title":"Front Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"917199","DOI":"10.3389\/FPSYT.2022.917199","article-title":"Psychedelics, Mystical experience, and therapeutic efficacy: a systematic review","volume":"13","author":"Ko","year":"2022","journal-title":"Front Psych"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/J.JAD.2022.12.042","article-title":"Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms","volume":"324","author":"Nikolaidis","year":"2023","journal-title":"J Affect Disord"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"813746","DOI":"10.3389\/FPSYG.2022.813746","article-title":"Virtual reality as a moderator of psychedelic-assisted psychotherapy","volume":"13","author":"Sekula","year":"2022","journal-title":"Front Psychol"},{"key":"ref12","first-page":"326","volume-title":"The varieties of psychedelic experience: the classic guide to the effects of LSD on the human psyche","author":"Masters","year":"2000"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1007\/S00213-022-06187-5","article-title":"The Watts connectedness scale: a new scale for measuring a sense of connectedness to self, others, and world","volume":"239","author":"Watts","year":"2022","journal-title":"Psychopharmacology"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1177\/0022167817709585","article-title":"Patients\u2019 accounts of increased \u201cconnectedness\u201d and \u201cacceptance\u201d after psilocybin for treatment-resistant depression","volume":"57","author":"Watts","year":"2017","journal-title":"J Humanist Psychol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s00213-017-4701-y","article-title":"Psychedelics and connectedness","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2055102920978123","DOI":"10.1177\/2055102920978123\/ASSET\/IMAGES\/LARGE\/10.1177_2055102920978123-FIG_1.JPEG","article-title":"The potential synergistic effects between psychedelic administration and nature contact for the improvement of mental health","volume":"7","author":"Gandy","year":"2020","journal-title":"Health Psychol Open"},{"key":"ref17","first-page":"69","article-title":"The biological basis for human values of nature","volume":"42","author":"Kellert","year":"1993","journal-title":"The Biophilia Hypothesis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1037\/0003-066X.55.1.15","article-title":"The evolution of happiness","volume":"55","author":"Buss","year":"2000","journal-title":"Am Psychol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1177\/1937586715595505","article-title":"The impact of simulated nature on patient outcomes: a study of photographic sky compositions","volume":"9","author":"Pati","year":"2016","journal-title":"Health Environ Res Des J"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1258\/jrsm.2010.100256","article-title":"Visual art in hospitals: case studies and review of the evidence","volume":"103","author":"Lankston","year":"2010","journal-title":"J R Soc Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1378\/chest.123.3.941","article-title":"Distraction therapy with nature sights and sounds reduces pain during flexible bronchoscopy: a complementary approach to routine analgesia","volume":"123","author":"Diette","year":"2003","journal-title":"Chest"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1177\/153331759701200506","article-title":"The effect of natural environments upon agitation and aggression in late stage dementia patients","volume":"12","author":"Whall","year":"1997","journal-title":"Am J Alzheimers Dis Other Dement"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"170","DOI":"10.15288\/JSAS.2005.S15.170","article-title":"A structured approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence","volume":"66","author":"Pettinati","year":"2005","journal-title":"J Stud Alcohol Suppl"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41386-020-00883-6","article-title":"Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects","volume":"46","author":"Holze","year":"2021","journal-title":"Neuropsychopharmacology"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/J.JAGP.2022.08.007","article-title":"The safety and efficacy of psychedelic-assisted therapies for older adults: knowns and unknowns","volume":"31","author":"Johnston","year":"2023","journal-title":"Am J Geriatr Psychiatry"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.3389\/FPSYT.2022.1017504\/BIBTEX","article-title":"Intravenous ketamine for depression: a clinical discussion reconsidering best practices in acute hypertension management","volume":"13","author":"Yip","year":"2022","journal-title":"Front Psych"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/ADB.13229","article-title":"Classic psychedelics and alcohol use disorders: a systematic review of human and animal studies","volume":"27","author":"Calleja-Conde","year":"2022","journal-title":"Addict Biol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1176\/APPI.AJP.2021.21030277","article-title":"Adjunctive ketamine with relapse prevention-based psychological therapy in the treatment of alcohol use disorder","volume":"179","author":"Grabski","year":"2022","journal-title":"Am J Psychiatry"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1176\/appi.ajp.2019.19070684","article-title":"A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial","volume":"177","author":"Dakwar","year":"2020","journal-title":"Am J Psychiatry"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3389\/fnins.2018.00129","article-title":"The meaning-enhancing properties of psychedelics and their mediator role in psychedelic therapy, spirituality, and creativity","volume":"12","author":"Hartogsohn","year":"2018","journal-title":"Front Neurosci"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1007\/S00213-014-3714-Z","article-title":"LSD enhances suggestibility in healthy volunteers","volume":"232","author":"Carhart-Harris","year":"2015","journal-title":"Psychopharmacology"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1215972\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T04:01:48Z","timestamp":1695096108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2023.1215972\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,18]]},"references-count":31,"alternative-id":["10.3389\/fpsyt.2023.1215972"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2023.1215972","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,18]]},"article-number":"1215972"}}